StockpollyBeta
Get App
Popularity #3,139
TARA · NASDAQ · Biotechnology

Protara Therapeutics (TARA)

Develops investigational therapies for cancer, lymphatic malformations, and patients receiving parenteral support.

$3.50
vs last close−0.19 (−5.03%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
111112111214141715192023
Research & development66868991110131317
454445565666
General & administrative454445565666
Operating income−11−11−12−11−12−14−14−17−15−19−20−23
111112222222
Interest income111111221220
Other non-operating income0−1−1−1−1−2−2−2−2−2−2−2
Income before tax−10−10−11−10−11−13−12−15−13−17−18−22
Net income from continuing operations−10−10−11−10−11−13−12−15−13−17−18−22
Net income−10−10−11−10−11−13−12−15−13−17−18−22
EPS, basic−$0.87−$0.90−$0.97−$0.45−$0.50−$0.48−$0.29−$0.35−$0.31−$0.38−$0.31−$0.36
EPS, diluted−$0.87−$0.90−$0.97−$0.45−$0.50−$0.48−$0.29−$0.35−$0.31−$0.38−$0.31−$0.36
Weighted average shares, basic111111212226414242465861
Weighted average shares, diluted111111212226414242465861
EBITDA−11−10−11−9−11−13−12−15−13−17−18−22
Depreciation & amortization000000000000
EBIT−11−10−11−10−11−13−12−15−13−17−18−22